Stemedica International, S.A., a wholly owned subsidiary of Stemedica Cell Technologies, Inc., announced the signing of an agreement to form a joint venture with AnC Bio, a global manufacturer of stem cell-based products. The new venture, StemedicaAnC, will manufacture allogeneic adult stem cells developed by Stemedica for the treatment of ischemic stroke and other degenerative disorders.
Stemedica International, S.A., ("Stemedica"), a wholly owned subsidiary of Stemedica Cell Technologies, Inc., announced the signing of an agreement to ...
A world leader in allogeneic adult stem cell manufacturing and research, Stemedica Cell Technologies, Inc. announced the completion of its proprietary master bank of mesenchymal bone marrow-derived stem cells.
Stemedica Cell Technologies, Inc., a world leader in allogeneic adult stem cell manufacturing and research, announced today that it has completed its ...
Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica's allogeneic adult stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.
Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem cell manufacturing, research and development announced today the appointment of C ...
Satisfied Users & 
Approved Press Releases
